NCT00005799 - Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

July 31, 2002

Conditions

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)B-cell Chronic Lymphocytic LeukemiaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionChildhood Chronic Myelogenous LeukemiaChildhood Myelodysplastic SyndromesChildhood Renal Cell CarcinomaChronic Phase Chronic Myelogenous LeukemiaClear Cell Renal Cell Carcinomade Novo Myelodysplastic SyndromesExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRefractory Multiple MyelomaRelapsing Chronic Myelogenous LeukemiaSplenic Marginal Zone LymphomaStage III Renal Cell CancerStage IV Renal Cell CancerT-cell Large Granular Lymphocyte LeukemiaType 1 Papillary Renal Cell CarcinomaType 2 Papillary Renal Cell CarcinomaWaldenström Macroglobulinemia

Interventions

DRUG

fludarabine phosphate

Given IV

RADIATION

total-body irradiation

Undergo low-dose TBI

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Undergo nonmyeloablative HSCT

PROCEDURE

allogeneic bone marrow transplantation

Undergo nonmyeloablative allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Undergo nonmyeloablative allogeneic PBSC transplantation

BIOLOGICAL

therapeutic allogeneic lymphocytes

Undergo DLI

DRUG

cyclosporine

Given PO

DRUG

mycophenolate mofetil

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (7)

75246

Baylor University Medical Center, Dallas

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

91010

City of Hope Medical Center, Duarte

94305

Stanford University Hospitals and Clinics, Stanford

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

80217-3364

University of Colorado, Denver

D-04103

Universitaet Leipzig, Leipzig

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER